Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Cascara bark (Frangula purshiana, syn. Rhamnus purshiana) contains anthraquinone glycosides—primarily cascarosides A–D, emodin, aloe-emodin, and chrysaloin—that are metabolized by colonic bacteria into aglycones which stimulate large intestine motility and electrolyte secretion, producing a well-characterized stimulant laxative effect. Research on its constituent emodin demonstrates significant antioxidant capacity and neuroprotective potential (PMID 35367766), while cytotoxicity profiling of structurally diverse anthranoids has clarified structure–activity relationships underlying both therapeutic efficacy and dose-dependent toxicity (PMID 30321134).
Reported Benefits (Provisional)
Origin & History
Cascara (Rhamnus purshiana) is a deciduous tree native to the moist coniferous forests and mountainous river valleys of western North America, particularly California, Oregon, and British Columbia. Its bark has been historically valued for its potent laxative and digestive cleansing properties.
Research Narrative (Provisional)
A comprehensive LiverTox/NCBI monograph (PMID 30000918) details cascara's pharmacology, confirming cascaroside-driven stimulant laxative activity and rare hepatotoxicity at excessive doses. Demarque et al. (2018) in the Journal of Pharmacy & Pharmaceutical Sciences (PMID 30321134) systematically evaluated the cytotoxicity of structurally diverse anthranoids—including emodin and aloe-emodin found in cascara—correlating chemical structure with mechanism of action and side-effect profiles. Brkanac et al. (2015) in Regulatory Toxicology and Pharmacology (PMID 26399165) assessed emodin's toxicity and antioxidant capacity in Frangula alnus (a closely related species), establishing dose-dependent oxidative stress modulation. Mitra et al. (2022) in Biomedicine & Pharmacotherapy (PMID 35367766) provided an extensive review of emodin's neuroprotective properties, demonstrating anti-inflammatory, anti-apoptotic, and antioxidant pathways relevant to cascara's bioactive profile.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Anthraquinones (cascarosides A & B, emodin, aloe-emodin): Provide stimulant laxative and choleretic (bile-stimulating) effects. - Flavonoids: Contribute to antioxidant and anti-inflammatory properties. - Tannins: Offer astringent properties that support gut lining integrity. - Resins: May contribute to its overall therapeutic effects.
Reported Mechanism (Provisional)
The primary active constituents—cascarosides A, B, C, and D—are C-glycosides of barbaloin and chrysaloin that resist hydrolysis in the upper gastrointestinal tract and are cleaved by β-glucosidases produced by colonic microbiota (e.g., Bifidobacterium and Eubacterium spp.) into free anthraquinone aglycones including emodin, aloe-emodin, and chrysophanol. These aglycones inhibit Na⁺/K⁺-ATPase on colonic epithelial cells and stimulate chloride channel (ClC-2) secretion, resulting in net water and electrolyte accumulation in the colonic lumen and accelerated peristalsis via activation of enteric neurons and prostaglandin E₂ release. Emodin additionally modulates NF-κB and MAPK signaling pathways, conferring anti-inflammatory and antioxidant effects in the gut mucosa (PMID 35367766). The choleretic effect is attributed to anthraquinone-mediated stimulation of bile acid synthesis via farnesoid X receptor (FXR) modulation and enhanced hepatobiliary secretion.
Clinical Narrative (Provisional)
Clinical evidence for cascara bark relies primarily on pharmacological studies and historical use rather than controlled human trials with quantified outcomes. The standard therapeutic dose is 300 mg once daily for no more than 6 days, or 1 ml aromatic fluid extract. While in vitro studies demonstrate the anthraquinone compounds' laxative mechanisms and emodin's potential anticancer activity through p53/p21 pathway activation, rigorous human clinical trials with statistical outcomes are lacking. The FDA classified cascara as not generally recognized as safe or effective for over-the-counter use in 2002 due to insufficient safety studies.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.